Literature DB >> 1706936

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides.

J M Lambert1, G McIntyre, M N Gauthier, D Zullo, V Rao, R M Steeves, V S Goldmacher, W A Blättler.   

Abstract

A glycopeptide containing a triantennary N-linked oligosaccharide from fetuin was modified by a series of chemical and enzymic reactions to afford a reagent that contained a terminal residue of 6-(N-methylamino)-6-deoxy-D-galactose on one branch of the triantennary structure and terminal galactose residues on the other two branches. Binding assays and gel filtration experiments showed that this modified glycopeptide could bind to the sugar-binding sites of ricin. The ligand was activated at the 6-(N-methylamino)-6-deoxy-D-galactose residue by reaction with cyanuric chloride. The resulting dichlorotriazine derivative of the ligand reacts with ricin, forming a stable covalent linkage. The reaction was confined to the B-chain and was inhibited by lactose. Bovine serum albumin and ovalbumin were not modified by the activated ligand under similar conditions, and we conclude, therefore, that the reaction of the ligand with ricin B-chain was dependent upon specific binding to sugar-binding sites. Ricin that had its galactose-binding sites blocked by the covalent reaction with the activated ligand was purified by affinity chromatography. The major species in this fraction was found to contain 2 covalently linked ligands per ricin B-chain, while a minor species contained 3 ligands per B-chain. The cytotoxicity of blocked ricin was at least 1000-fold less than that of native ricin for cultured cells in vitro, even though the activity of the A-chain in a cell-free system was equal to that from native ricin. Modified ricin that contained only 1 covalently linked ligand was also purified. This fraction retained an ability to bind to galactose affinity columns, although with a lower affinity than ricin, and was only 5- to 20-fold less cytotoxic than native ricin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706936     DOI: 10.1021/bi00227a011

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Authors:  Richard R Furman; Michael L Grossbard; Jeffrey L Johnson; Andrew L Pecora; Peter A Cassileth; Sin-Ho Jung; Bruce A Peterson; Lee M Nadler; Arnold Freedman; Ruthee-Lu Bayer; Nancy L Bartlett; David D Hurd; Bruce D Cheson
Journal:  Leuk Lymphoma       Date:  2011-01-28

2.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 4.  Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Authors:  Yingzhi Chen; Meng Zhang; Kyoung Ah Min; Huiyuan Wang; Meong Cheol Shin; Feng Li; Victor C Yang; Yongzhuo Huang
Journal:  Curr Drug Targets       Date:  2018-02-19       Impact factor: 3.465

5.  Modification of ricin and its hepatotoxicity and activity against hepatocellular cancer in mice.

Authors:  Wen-Xue Wang; Ju-Ying Dong; Si-Yuan Zhou; Wen-Li Li; Ying Zhao
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

6.  Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.

Authors:  D C Roy; C Perreault; R Bélanger; M Gyger; C Le Houillier; W A Blättler; J M Lambert; J Ritz
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

Review 7.  Chemical construction of immunotoxins.

Authors:  V Ghetie; E S Vitetta
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.860

Review 8.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 9.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

10.  Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.

Authors:  U Zangemeister-Wittke; A R Collinson; B Frösch; R Waibel; T Schenker; R A Stahel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.